利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

105 条记录 (耗时 0.023 秒)

    Nanaomycin B and therapeutic compositions containing same
    1.
    发明授权
    Nanaomycin B and therapeutic compositions containing same 失效
    纳那霉素B和含有其的治疗组合物

    公开(公告)号：US4308210A

    公开(公告)日：1981-12-29

    申请号：US43396

    申请日：1979-05-25

    申请人： Satoshi Omura ,  Haruo Tanaka ,  Juichi Awaya ,  Toju Hata

    发明人： Satoshi Omura ,  Haruo Tanaka ,  Juichi Awaya ,  Toju Hata

    IPC分类号： C07D311/92 ,  A61K31/35 ,  A61K31/352 ,  A61P17/00 ,  A61P31/04 ,  C12P17/06 ,  C07D311/78

    CPC分类号： C12R1/465 ,  C12P17/06

    摘要： The present invention relates to new compound designated as nanaomycin B represented by general formula: ##STR1## Nanaomycin B is a quinone type and is active on mycoplasma, Gram-positive bacteria and trycophyton. This compound is useful as a medicament for infectious diseases of humans and animals caused by a parasite of trichophyton or mycoplasma etc. The acute toxicity (LD.sub.50, intra-penetrial injection) in mice of this compound is 169 mg/Kg.Nanaomycin B is produced by fermentation in which a nanaomycin-producing strain belonging to the genus Streptomyces is cultured in a medium under aerobic conditions and the accumulated nanaomycin B in the cultured broths is recovered therefrom.

    摘要翻译： 本发明涉及以通式表示的纳那霉素B的新化合物：＆lt; IMAGE＆gt; Nanaomycin B是醌类，对支原体，革兰氏阳性菌和真菌是有活性的。 该化合物可用作由毛发虫或支原体寄生虫引起的人和动物感染性疾病的药物。该化合物小鼠的急性毒性（LD50，渗透内注射）为169mg / Kg。 纳豆霉素B通过发酵生产，其中在需氧条件下培养在属于链霉菌属的纳米霉素生产菌株，并从其中回收培养肉汤中积累的纳诺霉素B.

    Compound nanaomycin A and derivatives thereof and a process for producing the same
    2.
    发明授权
    Compound nanaomycin A and derivatives thereof and a process for producing the same 失效
    复方纳诺霉素A及其衍生物及其制备方法

    公开(公告)号：US4324728A

    公开(公告)日：1982-04-13

    申请号：US47451

    申请日：1979-06-11

    申请人： Satoshi Omura ,  Haruo Tanaka ,  Juichi Awaya ,  Toju Hata

    发明人： Satoshi Omura ,  Haruo Tanaka ,  Juichi Awaya ,  Toju Hata

    IPC分类号： C07D311/92 ,  A61K31/35 ,  A61K31/352 ,  A61P31/04 ,  C12P7/66 ,  C12P17/06

    CPC分类号： C12R1/465 ,  C12P17/06

    摘要： The present invention relates to new compound nanaomycin A and derivatives thereof represented by general formula: ##STR1## in which (a) R is H and R' is OH (nanaomycin A),(b) R is H and R' is NH.sub.2 (nanaomycin C),(c) R is COCH.sub.3 and R' is OH (acetylnanaomycin A), and(d) R is H and R' is OCH.sub.3 (nanaomycin A methyl ester).Nanaomycin A is a new compound of quinone type and its acute toxicity (LD.sub.50, intra-penetrial injection) in mice is 28.2 mg/Kg. Nanaomycin A and derivatives thereof are active on Gram-positive bacteria, trichophyton and mycoplasma and are useful as a medicament for humans and animals. Nanaomycins A and C are produced by culturing a nanaomycin-producing strain belonging to the genus Streptomyces aerobically in a medium to accumulate nanaomycins A and C in the cultured broths. The derivatives acetylnanaomycin A and nanaomycin A methyl ester have similar properties to those of nanaomycin A.

    摘要翻译： 本发明涉及由以下通式表示的新化合物纳那霉素A及其衍生物：其中（a）R是H，R'是OH（纳那霉素A），（b）R是H和R' 是NH2（纳那霉素C），（c）R是COCH 3，R'是OH（乙酰氨基霉素A），和（d）R是H，R'是OCH 3（纳诺霉素A甲酯）。 Nanaomycin A是醌类的新化合物，其在小鼠中的急性毒性（LD50，内渗注射）为28.2mg / Kg。 纳诺霉素A及其衍生物对革兰氏阳性菌，毛毛虫和支原体具有活性，可用作人和动物的药物。 Nanaomycins A和C通过在培养基中培养产生链霉菌属的链霉菌属的纳米霉素生产菌株在培养基中培养以在培养的肉汤中积累纳米菌素A和C而产生。 乙酰纳他霉素A和纳那霉素A甲酯的衍生物具有与纳那霉素A相似的性质。

    Production of nanaomycin A and derivatives thereof
    3.
    发明授权
    Production of nanaomycin A and derivatives thereof 失效
    生产纳诺霉素A及其衍生物

    公开(公告)号：US4196266A

    公开(公告)日：1980-04-01

    申请号：US858215

    申请日：1977-12-07

    申请人： Satoshi Omura ,  Haruo Tanaka ,  Juichi Awaya ,  Toju Hata

    发明人： Satoshi Omura ,  Haruo Tanaka ,  Juichi Awaya ,  Toju Hata

    IPC分类号： C12P17/06 ,  C12D9/14

    CPC分类号： C12R1/465 ,  C12P17/06 ,  Y10S435/886

    摘要： The present invention relates to new compound nanaomycin A and derivatives thereof represented by general formula: ##STR1## in which (a) R is H and R' is OH (nanaomycin A),(b) R is H and R' is NH.sub.2 (nanaomycin C),(c) R is COCH.sub.3 and R' is CH (acetylnanaomycin A), and(d) R is H and R' is OCH.sub.3 (nanaomycin A methyl ester).Nanaomycin A is a new compound of quinone type and its acute toxicity (LD.sub.50, intra-penetrial injection) in mice is 28.2 mg/Kg. Nanaomycin A and derivatives thereof are active on Gram-positive bacteria, trichophyton and mycoplasma and are useful as a medicament for humans and animals. Nanaomycins A and C are produced by culturing a nanaomycin-producing strain belonging to the genus Streptomyces aerobically in a medium to accumulate nanaomycins A and C in the cultured broths. The derivatives acetylnanaomycin A and nanaomycin A methyl ester have similar properties to those of nanaomycin A.

    摘要翻译： 本发明涉及由以下通式表示的新化合物纳那霉素A及其衍生物：其中（a）R是H，R'是OH（纳那霉素A），（b）R是H和R' 是NH2（纳那霉素C），（c）R是COCH 3，R'是CH（乙酰氨基霉素A），和（d）R是H，R'是OCH 3（纳诺霉素A甲酯）。 Nanaomycin A是醌类的新化合物，其在小鼠中的急性毒性（LD50，内渗注射）为28.2mg / Kg。 纳诺霉素A及其衍生物对革兰氏阳性菌，毛毛虫和支原体具有活性，可用作人和动物的药物。 Nanaomycins A和C通过在培养基中培养产生链霉菌属的链霉菌属的纳米霉素生产菌株在培养基中培养以在培养的肉汤中积累纳米菌素A和C而产生。 乙酰纳他霉素A和纳那霉素A甲酯的衍生物具有与纳那霉素A相似的性质。

    Production of nanaomycin B
    4.
    发明授权
    Production of nanaomycin B 失效
    生产纳诺霉素B

    公开(公告)号：US4194064A

    公开(公告)日：1980-03-18

    申请号：US858216

    申请日：1977-12-07

    申请人： Satoshi Omura ,  Haruo Tanaka ,  Juichi Awaya ,  Toju Hata

    发明人： Satoshi Omura ,  Haruo Tanaka ,  Juichi Awaya ,  Toju Hata

    IPC分类号： C12P17/06 ,  C12D9/14

    CPC分类号： C12R1/465 ,  C12P17/06 ,  Y10S435/886

    摘要： The present invention relates to new compound designated as nanaomycin B represented by general formula: ##STR1## Nanaomycin B is a quinone type and is active on mycoplasma, Gram-positive bacteria and trycophyton. This compound is useful as a medicament for infectious diseases of humans and animals caused by a parasite of trichophyton or mycoplasma etc. The acute toxicity (LD.sub.50, intra-penetrial injection) in mice of this compound is 169 mg/kg. Nanaomycin B is produced by fermentation in which a nanaomycin-producing strain belonging to the genus Streptomyces is cultured in a medium under aerobic conditions and the accumulated nanaomycin B in the cultured broths is recovered therefrom.

    摘要翻译： 本发明涉及以通式表示的纳那霉素B的新化合物：＆lt; IMAGE＆gt; Nanaomycin B是醌类，对支原体，革兰氏阳性菌和真菌是有活性的。 该化合物可用作由毛癣菌或支原体寄生虫等引起的人类和动物感染性疾病的药物。该化合物小鼠的急性毒性（LD50，内渗注射）为169mg / kg。 纳豆霉素B通过发酵生产，其中在需氧条件下培养在属于链霉菌属的纳米霉素生产菌株，并从其中回收培养肉汤中积累的纳诺霉素B.

    Antibiotic composition
    7.
    发明授权
    Antibiotic composition 失效
    抗生素组成

    公开(公告)号：US4226879A

    公开(公告)日：1980-10-07

    申请号：US939102

    申请日：1978-09-01

    申请人： Satoshi Omura ,  Chiaki Kitao ,  Akira Nakagawa ,  Haruo Tanaka ,  Juichi Awaya ,  Ruiko Oiwa

    发明人： Satoshi Omura ,  Chiaki Kitao ,  Akira Nakagawa ,  Haruo Tanaka ,  Juichi Awaya ,  Ruiko Oiwa

    IPC分类号： A23K20/195 ,  A61K31/335 ,  A61K35/00 ,  C07D303/06

    CPC分类号： A23K20/195

    摘要： The present invention relates to a new composition designated as AM-1042 or asukamycin. AM-1042 has an antibiotic activity upon Gram-positive bacteria and Eimeria, and its acute toxicity (LD.sub.50 ' ip.) in mice was 48.5 mg./kg. AM-1042 has an excellent therapeutical effect on various infectious diseases caused by a parasite of Gram-positive bacteria and Eimeria. AM-1042 has been confirmed to be distinguishable from known antibiotics such as e.g. amicetin B, azomycin and manumycin. AM-1042 is produced by fermentation of a microorganism belonging to the genus Streptomyces and capable of producing AM-1042. A composition capable of preventing and curing coccidiosis of poultry containing AM-1042 as active ingredient.

    摘要翻译： 本发明涉及一种称为AM-1042或无菌素的新组合物。 AM-1042对革兰氏阳性菌和艾美球虫具有抗菌活性，其在小鼠中的急性毒性（LD50'ip。）为48.5mg./kg。 AM-1042对由革兰氏阳性菌和艾美球虫寄生虫引起的各种感染性疾病具有极好的治疗作用。 已证实AM-1042可与已知的抗生素区别，例如： amicetin B，azomycin和manumycin。 AM-1042是通过发酵属于链霉菌属的微生物并产生AM-1042产生的。 一种能够预防和治疗含有AM-1042作为活性成分的家禽的球虫病的组合物。

    Antibiotic OS-3256-B
    10.
    发明授权
    Antibiotic OS-3256-B 失效
    抗生素OS-3256-B

    公开(公告)号：US3995028A

    公开(公告)日：1976-11-30

    申请号：US606687

    申请日：1975-08-21

    申请人： Satoshi Omura ,  Iwao Umezawa ,  Keiki Satoh ,  Juichi Awaya ,  Kanki Komiyama ,  Ruiko Oiwa

    发明人： Satoshi Omura ,  Iwao Umezawa ,  Keiki Satoh ,  Juichi Awaya ,  Kanki Komiyama ,  Ruiko Oiwa

    IPC分类号： C07G11/00 ,  A61K35/74

    CPC分类号： A61K36/06 ,  C07G11/00 ,  Y10S435/892

    摘要： The present invention relates to a new antibiotic designated as OS-3256-B. OS-3256-B exhibits excellent inhibitory activities against animal tumors such as leukemia L-1210, Sarcoma-180 and Hela cells and gram-positive bacteria and is classified into the diazocompounds group. However, chromatographic analysis, Rf value and other experimental data reveal that OS-3256-B is a new compound of the type of azaamino acid derivatives. The present invention also provides a process for producing OS-3256-B by fermentation, in which OS-3256-B is produced by culturing a microorganism belonging to Streptomyces candidus var. azaticus in a culture medium conventionally used for culturing Streptomyces strain microorganisms.

    摘要翻译： 本发明涉及一种称为OS-3256-B的新型抗生素。 OS-3256-B对动物肿瘤例如白血病L-1210，肉瘤180和Hela细胞和革兰氏阳性细菌具有优异的抑制活性，并被分类为重氮化合物组。 然而，色谱分析，Rf值等实验数据表明，OS-3256-B是一种新型的氮杂氨基酸衍生物化合物。 本发明还提供了通过发酵生产OS-3256-B的方法，其中OS-3256-B是通过培养属于Streptomyces candidus var。 通常用于培养链霉菌菌株微生物的培养基中的azaticus。